As global markets respond to favorable trade deal news, Asian equities have shown resilience amid ongoing tariff discussions and economic uncertainties. In this environment, identifying undervalued stocks—those trading below their intrinsic value—can offer potential opportunities for investors looking to capitalize on market inefficiencies.
Name
Current Price
Fair Value (Est)
Discount (Est)
Shin Maint HoldingsLtd (TSE:6086)
¥1174.00
¥2321.82
49.4%
Shenzhen KSTAR Science and Technology (SZSE:002518)
CN¥23.34
CN¥46.18
49.5%
Range Intelligent Computing Technology Group (SZSE:300442)
CN¥51.15
CN¥101.32
49.5%
Polaris Holdings (TSE:3010)
¥220.00
¥433.40
49.2%
Nan Ya Printed Circuit Board (TWSE:8046)
NT$177.00
NT$350.10
49.4%
LigaChem Biosciences (KOSDAQ:A141080)
₩139000.00
₩277490.02
49.9%
Hibino (TSE:2469)
¥2345.00
¥4664.61
49.7%
Heartland Group Holdings (NZSE:HGH)
NZ$0.82
NZ$1.62
49.4%
Forum Engineering (TSE:7088)
¥1206.00
¥2405.10
49.9%
Andes Technology (TWSE:6533)
NT$274.50
NT$542.92
49.4%
Below we spotlight a couple of our favorites from our exclusive screener.
Overview: Dongsung FineTec Co., Ltd. is a South Korean company that manufactures and sells cryogenic insulation products, with a market cap of approximately ₩811.48 billion.
Operations: The company’s revenue segments include the Gas Business, generating approximately ₩23.03 billion, and Cooling Material, contributing around ₩609.47 billion.
Estimated Discount To Fair Value: 26.2%
Dongsung FineTec is trading at ₩27,950, significantly undervalued compared to its estimated fair value of ₩37,869.08. Its earnings are projected to grow at 22.6% annually, outpacing the Korean market’s growth rate and reflecting robust financial health despite an unstable dividend track record. Recent quarterly results showed net income of KRW 9 billion, up from KRW 8.69 billion a year earlier, reinforcing its strong cash flow position in the Asian market.
KOSDAQ:A033500 Discounted Cash Flow as at Jul 2025
Overview: Nanjing Vazyme Biotech Co., Ltd provides technology solutions in life science, biomedicine, and in vitro diagnostics with a market cap of CN¥10.52 billion.
Operations: Nanjing Vazyme Biotech Co., Ltd generates revenue through its technology solutions in life science, biomedicine, and in vitro diagnostics.
Story Continues
Estimated Discount To Fair Value: 17.1%
Nanjing Vazyme Biotech is trading at CN¥26.44, slightly below its fair value estimate of CN¥31.91, suggesting it may be undervalued based on cash flows. The company is expected to become profitable within three years, with earnings projected to grow 78.27% annually—surpassing market averages despite a low forecasted return on equity of 5.6%. A recent share buyback plan worth CN¥10 million aims to enhance shareholder value through potential equity incentives or employee stock ownership plans.
SHSE:688105 Discounted Cash Flow as at Jul 2025
Overview: Zhejiang Yinlun Machinery Co., Ltd. focuses on the research, development, manufacturing, and sale of thermal management and exhaust gas post-treatment products, with a market cap of CN¥24.97 billion.
Operations: The company generates revenue primarily from the sale of thermal management and exhaust gas post-treatment products.
Estimated Discount To Fair Value: 12.7%
Zhejiang Yinlun Machinery is trading at CN¥30.13, undervalued relative to its fair value estimate of CN¥34.53. Earnings grew 18.9% last year and are projected to rise 25.12% annually, outpacing the Chinese market’s growth rate of 23.5%. Despite a lower future return on equity forecast of 16.1%, recent share buybacks totaling CN¥34.96 million may enhance shareholder value through equity incentives or employee stock ownership plans.
SZSE:002126 Discounted Cash Flow as at Jul 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSDAQ:A033500 SHSE:688105 and SZSE:002126.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com